Low-Dose Interleukin 2 for Primary Sjögren Syndrome

 

Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome

A Randomized Clinical Trial

This study found that LD-IL-2 was effective and well-tolerated in patients with Primary Sjogren's Syndrome (pSS). The clinical benefits might result from the effect of IL-2 to restore the balance of T and B cell subsets.

The management of pSS is challenging due to the diverse nature of the disease and lack of safe, effective, and specifically targeted therapies.

We have shown that LD-IL-2 confers benefits for the treatment of patients with pSS and resulted in a significant clinical improvement in ESSDAI, ESSPRI, and SF-36 MCS scores, as well as organ involvement including pulmonary lesions among patients with pSS. ~ Jing He, MD; Jiali Chen, MD; Miao Miao, PhD; et al

 READ THE FULL REPORT 

GLOSSARY

Low-Dose Interleukin 2 LD-IL-2: Interleukin 2 (IL-2) is the key cytokine that regulates the homeostasis and activation of CD4⁺ T cells.⁴ It is required for the development, proliferation, and survival of regulatory T cells (Tregs).

T and B cell subsets: 

• B lymphocytes (B cells). These make antibodies that help your body fight infections. 
• T lymphocytes (T cells). These attack foreign cells, cancer cells, and cells infected with a virus.

ESSDAI: European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index.  The ESSDAI includes 12 domains, as follows: cutaneous, respiratory, kidney, articular, muscular, peripheral nervous system, central nervous system, hematological, glandular, constitutional, lymphadenopathic, and immunological, with a total score ranging from 0 to 123 points.

ESSPRI: European Alliance of Associations for Rheumatology SS Patient Reported Index

SF-36 : Short Form Survey